Reply to Arends and Harkisoen
- PMID: 25313251
- PMCID: PMC4275062
- DOI: 10.1093/cid/ciu800
Reply to Arends and Harkisoen
Comment on
-
Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome: a comparative observational study.Clin Infect Dis. 2014 Sep 15;59(6):851-7. doi: 10.1093/cid/ciu449. Epub 2014 Jun 13. Clin Infect Dis. 2014. PMID: 24928291
-
Efficacy of polyspecific intravenous immunoglobulin therapy in streptococcal toxic shock syndrome.Clin Infect Dis. 2015 Jan 15;60(2):324. doi: 10.1093/cid/ciu799. Epub 2014 Oct 13. Clin Infect Dis. 2015. PMID: 25313253 No abstract available.
References
-
- Arends JE, Harkisoen S. Efficacy of polyspecific intravenous immunoglobulin therapy in streptococcal toxic shock syndrome. Clin Infect Dis. 2015;60:324. - PubMed
-
- Linnér A, Darenberg J, Sjölin J, Henriques-Normark B, Norrby-Teglund A. Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome: a comparative observational study. Clin Infect Dis. 2014;59:851–7. - PubMed
-
- Darenberg J, Luca-Harari B, Jasir A, et al. Molecular and clinical characteristics of invasive group A streptococcal infections in Sweden. Clin Infect Dis. 2007;45:450–8. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
